These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 18676840

  • 1. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.
    Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J, Jansen M, Schleimer D, Nattamai K, Wilhelm J, Watson A, Geiger H, Margison GP, Moritz T, Baum C, Thomale J, Williams DA.
    Cancer Res; 2008 Aug 01; 68(15):6171-80. PubMed ID: 18676840
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S, Seshadri R, Pegg AE, Williams DA.
    Cancer Res; 2000 Sep 15; 60(18):5187-95. PubMed ID: 11016647
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
    Schambach A, Baum C.
    DNA Repair (Amst); 2007 Aug 01; 6(8):1187-96. PubMed ID: 17482894
    [Abstract] [Full Text] [Related]

  • 6. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
    Fontes AM, Davis BM, Encell LP, Lingas K, Covas DT, Zago MA, Loeb LA, Pegg AE, Gerson SL.
    Mol Cancer Ther; 2006 Jan 01; 5(1):121-8. PubMed ID: 16432170
    [Abstract] [Full Text] [Related]

  • 7. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL, Pollok KE, Bailey BJ, Liu N, Hartwell JR, Williams DA, Erickson LC.
    Mol Cancer Ther; 2003 Dec 01; 2(12):1321-9. PubMed ID: 14707273
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
    Maze R, Kurpad C, Pegg AE, Erickson LC, Williams DA.
    J Pharmacol Exp Ther; 1999 Sep 01; 290(3):1467-74. PubMed ID: 10454526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
    Woolford LB, Southgate TD, Margison GP, Milsom MD, Fairbairn LJ.
    J Gene Med; 2006 Jan 01; 8(1):29-34. PubMed ID: 16075413
    [Abstract] [Full Text] [Related]

  • 13. Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.
    Phaltane R, Haemmerle R, Rothe M, Modlich U, Moritz T.
    Hum Gene Ther; 2014 Feb 01; 25(2):144-55. PubMed ID: 24218991
    [Abstract] [Full Text] [Related]

  • 14. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro.
    Zielske SP, Gerson SL.
    Mol Ther; 2002 Apr 01; 5(4):381-7. PubMed ID: 11945064
    [Abstract] [Full Text] [Related]

  • 15. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.
    Ball CR, Pilz IH, Schmidt M, Fessler S, Williams DA, von Kalle C, Glimm H.
    Blood; 2007 Sep 15; 110(6):1779-87. PubMed ID: 17496202
    [Abstract] [Full Text] [Related]

  • 16. Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker.
    Choi U, DeRavin SS, Yamashita K, Whiting-Theobald N, Linton GF, Loktionova NA, Pegg AE, Malech HL.
    Exp Hematol; 2004 Aug 15; 32(8):709-19. PubMed ID: 15308322
    [Abstract] [Full Text] [Related]

  • 17. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
    Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL.
    J Clin Invest; 2003 Nov 15; 112(10):1561-70. PubMed ID: 14617757
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL.
    Hum Gene Ther; 1999 Nov 20; 10(17):2769-78. PubMed ID: 10584923
    [Abstract] [Full Text] [Related]

  • 19. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
    Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP.
    Mol Ther; 2001 Jan 20; 3(1):78-87. PubMed ID: 11162314
    [Abstract] [Full Text] [Related]

  • 20. Methylguanine DNA methyltransferase-mediated drug resistance-based selective enrichment and engraftment of transplanted stem cells in skeletal muscle.
    Lee AS, Kahatapitiya P, Kramer B, Joya JE, Hook J, Liu R, Schevzov G, Alexander IE, McCowage G, Montarras D, Gunning PW, Hardeman EC.
    Stem Cells; 2009 May 20; 27(5):1098-108. PubMed ID: 19415780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.